ABHD17C

Across TCGA pan-cancer cohorts, ABHD17C mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ABHD17C’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where ABHD17C mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ABHD17C is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

PDAC, HNSC, and LUAD are the cancer types where ABHD17C tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ABHD17C mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	III,IV	+0.930	<.001	9	view →
HNSC	Male	IV	−0.611	<.001	8	view →
LUAD	Female	III,IV	−0.857	<.001	7	view →
LSCC	Male	All	−0.391	<.001	6	view →
CCRCC	All	III,IV	−1.737	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ABHD17C–PDAC

Open the PDAC breakdown →